As shown in Table 4, we evaluated the correlation between FMNL1 and immune cell subtypes in breast cancer and found that it was positively correlated with the vast majority of immune cell subtypes but negatively with the gene marker GATA3 in TH2 cells, demonstrating the worse prognosis of BrCa and high correlation of the immunotherapy of PD-L1 and CTLA4. The gene discussed is GATA3; the disease is breast carcinoma.